Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by St-Gennain, G.
Right arrow Articles by Repentigny, L. d.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by St-Gennain, G.
Right arrow Articles by Repentigny, L. d.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1995) 36, 109-118
© 1995 The British Society for Antimicrobial Chemotherapy

research-article

Ketoconazole and itraconazole susceptibility of Candida albicans isolated from patients infected with HIV

Guy St-Gennaina, Christiane Dionb, Ana Espinel-Ingroffc, Johanne Ratellec and Louis de Repentignyc,*

aQuebec Public Health Laboratory 20045 chemin Sainte Marie, Sainte-Anne-de-Bellevue, Quebec, Canada H9X 3R5 bMedical College of Virginia Richmond, Virginia 23298–0049, USA cSainte-Justine Hospital Montreal, Quebec, Canada H3T 1C5

Received 14 June 1994; returned 18 August 1994; accepted 8 February 1995

*Phone: + l-(514)-4572070. Fax- + l-(5)4)-4576346

Two hundred and fifty-five isolates of Candida albicans were collected from 93 patients infected with HIV during the course of a clinical trial comparing ketoconazole with itraconazole for the treatment of oropharyngeal or oesophageal candidosis. The susceptibility of the isolates to both drugs was determined by incubating 0.5–2.0 x104CFU/mL yeast in 0.25–16mg/L drug in RPMI1640 buffered with MOPS for 24 h at 35°C in 5%CO3 in microtitre trays. Each plate was agitated before reading the optical density. The IC90, IC80 and IC50 were defined as the lowest drug concentration to reduce the optical density to ≥90% 80% and 50% of the growth control respectively. IC90s >0.25 mg/L of ketoconazole and/or itraconazole were found for 42 isolates recovered from 21 patients, 12 of whom had responsed to treatment. IC80s >0.25 mg/L were found for only six of these isolates which had been recovered from three patients, two of whom responded well to treatment. These results indicate that neither the IC50 nor the IC80 are useful in predicting clinical resistance. None of the isolates exhibited IC50 > 0.25 mg/L to either drug which is consistent with the low incidence of resistance reported for these antifungal agents.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
J. H. Rex, M. A. Pfaller, T. J. Walsh, V. Chaturvedi, A. Espinel-Ingroff, M. A. Ghannoum, L. L. Gosey, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, et al.
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges
Clin. Microbiol. Rev., October 1, 2001; 14(4): 643 - 658.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
{blacktriangledown}Meropenem - an advantageous antibiotic?
DTB, July 1, 1996; 34(7): 53 - 55.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.